Special Issue

Amorphous Formulations and Solid-State Strategies to Improve Oral Drug Performance: Bridging Enabling Technologies, Biopharmaceutics, and Patient-Centric Product Design

Message from the Guest Editors

Poor aqueous solubility remains a major barrier in drug discovery and pharmacotherapy. Limited dissolution can reduce clinical response and drives early attrition; many development candidates fail because adequate exposure cannot be reached with practical oral doses. One widely used strategy is to generate amorphous drug forms, where loss of long-range order removes lattice-energy constraints and can increase apparent solubility and dissolution rate. These benefits are accompanied by challenges. Amorphous materials may recrystallize or undergo physical changes during storage. Formulation and manufacturing also present hurdles, such as polymer selection, processing method (e.g., spray drying or hot-melt extrusion), scale-up, and defining quality attributes for regulatory approval. researchers to contribute original studies and reviews on amorphous formulations and solid-state strategies that enhance dissolution and oral drug performance. Topics of interest include preformulation, processing, characterization, stability, biopharmaceutics, and patient-centric dosage form design.

Guest Editors

Dr. Réka Angi

1. Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9., H-1092 Budapest, Hungary
2. Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary

Dr. Nikolett Kállai-Szabó

1. Department of Pharmaceutics, Semmelweis University, Hőgyes E. Str. 7, 1092 Budapest, Hungary
2. Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői Str. 26., 1085 Budapest, Hungary

Deadline for manuscript submissions

31 July 2026

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/266479

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).

MDPI